Pharma BD Deal Intelligence
Roche's Jean-Jacques Garaud said the deal augments Roche's HCV portfolio with additional modes of action that could lead to interferon-free combinations,…
Roche terminated setrobuvir development in July 2015 after Phase 2b, as Gilead's sofosbuvir-based regimens reset the HCV standard of care and made non-nuke…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Roche to acquire Anadys at $3.70/share cash, ~$230M (256% premium). Strengthened Roche HCV portfolio with setrobuvir Phase 2 candidate.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Anadys Pharmaceuticals, Inc. (this deal) | 2010 | $230M | 16 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2010 deals · Roche Holding AG deals · Infectious Disease deals